Oculis CEO Will Present Data at AAO 2026
The company will highlight drug candidates for eye disease in New Orleans on October 8 and 9, 2026.
Updated on Oct. 7, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize long-term patient health over clinical trial success?
Oculis CEO Riad Sherif will present at the upcoming Eyecelerator @ AAO 2026 conference in New Orleans on October 8, 2026. Following the presentation, the company will sponsor the Neuro-Ophthalmology Subspecialty Day at the American Academy of Ophthalmology 2026 Annual Meeting on October 9, 2026.
Why it matters
The company seeks to demonstrate its commitment to neuro-ophthalmology through scientific exchange at the major industry event. These appearances will provide a platform to discuss progress on its drug pipeline as it approaches key clinical milestones.
Licaminlimab is a topical anti-TNFα candidate developed using single chain antibody fragment technology. Privosegtor is a peptoid small-molecule designed to cross blood-brain and retinal barriers, currently holding Breakthrough Therapy designation.
The players
Riad Sherif
He is the Chief Executive Officer of Oculis and will lead the company presentations in New Orleans.
Oculis
Based in Zug, Switzerland, this company focuses on developing ophthalmic therapies to address unmet patient needs.
The details
Oculis is testing Licaminlimab in the PREDICT-1 registrational trial for patients with TNFR1-mediated dry eye disease. Additionally, the company is advancing Privosegtor, which has received Orphan Drug status from both the FDA and the European Medicines Agency.
Timeline
October 8, 2026: Riad Sherif presents at Eyecelerator @ AAO 2026.
October 9, 2026: Oculis sponsors Neuro-Ophthalmology Subspecialty Day at AAO.
Year-end 2026: PREDICT-1 trial topline results are expected.
The Tech Race
The development of Licaminlimab follows a pattern set by other modern ophthalmological treatments utilizing single chain antibody fragment technology to improve drug delivery. This move positions the company to compete against legacy treatment paradigms in the dry eye disease market.
The potential success of these candidates could transform the treatment paradigm for patients suffering from dry eye disease and optic neuritis. The company's progress provides a look at how new drug delivery mechanisms may eventually simplify medical routines for chronic eye conditions.
The takeaway
Oculis is positioning its proprietary drug candidates for a major regulatory push as it reaches key data milestones. Investors and clinicians should watch for the upcoming clinical results to determine the efficacy of these new therapeutic approaches.
What happens next
Topline results from the PREDICT-1 registrational symptoms trial are expected to be released around year-end 2026.
Further reading
For more on industry advancements, visit the Biotech section.
More information
View the latest Oculis corporate information on their official website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust pharmaceutical companies to prioritize long-term patient health over clinical trial success?
